Approval · Notice of Compliance 9912 · 2008
RETAVASE: Notice of Compliance 9912
Issued November 28, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9912
- Date
- November 28, 2008
- Company
- Ekr Therapeutics IncCary, North Carolina, United States
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Thrombolytic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RETAVASE | Not yet assigned | — |
Medicinal ingredients
- RETEPLASE 10.4 UNIT per VIAL